Macular Edema Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Macular edema is a slowly progressing disease where accumulation of fluid takes place in a specialized part of the retina called the macula. Owing to the fluid retention in the retinal layer, the person may suffer from blurred or wavy central vision and/or change in appearance of colors. Most of macular edema cases are caused due to diabetes, wherein the blood vessels in the retina are usually damaged due to leakage of fluids, such as small amounts of blood. Other reasons that can lead to macular edema are side effects of certain medications, retinal vein occlusion, and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Increase in the prevalence and incidence of diabetes has increased the risk of diabetic macular edema, making it the major driver of the market. Furthermore, increased use of off-label drugs, such as Avastin (bevacizumab) by Roche, and the emergence of new drugs in the market further boost the market growth. Moreover, recently two drugs Ozurdex manufactured by Allergan and Lucentis developed by Roche and Novartis, which are used for the treatment of macular edema, received regulatory approvals, thus boosting the market growth. Furthermore, rise in funding for the R&D activities to tackle the burden of these chronic diseases by medical organizations and pharmaceuticals companies boosts the market.

The global macular edema market is segmented based on type, end user, and region. Based on type, it is bifurcated into cystoid macular edema and diabetic macular edema. Based on end user, it is divided into hospitals, ophthalmic clinics, research institutes, and contract research organizations. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major players, such as Acucela Inc., BCN Peptides, Aerie Pharmaceuticals, Inc., Aerpio Therapeutics, Inc., Amakem NV, Biomar Microbial Technologies, Antisense Therapeutics Limited, Charlesson LLC., Araim Pharmaceuticals, Inc., and Coherus BioSciences, are also provided in this report.

Key Benefits

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global macular edema market to identify the prevailing market opportunities.
• The projections in this report are made by analyzing the current trends and future market potential in terms of value.
• Competitive intelligence helps to understand the competitive scenario across the geographies.
• An in-depth analysis of current research and clinical developments within market is provided with key dynamic factors that help understand the market behavior.

  Macular Edema Market Report Highlights

Aspects	Details
By Type	Cystoid Macular Edema Diabetic Macular Edema
By End User	Hospitals Ophthalmic Clinics Research Institutes Contract Research Organizations
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Charlesson LLC., Amakem NV, BCN Peptides, Coherus BioSciences, Acucela Inc., Antisense Therapeutics Limited, Biomar Microbial Technologies, Aerpio Therapeutics, Inc., Aerie Pharmaceuticals, Inc., Araim Pharmaceuticals, Inc.

^*Terms and Conditions Apply